In this multicentre phase 3 study , patients with clear cell metastatic renal cell carcinoma who received one previous VEGF-targeted therapy and one previous mTOR inhibitor were randomly assigned through an interactive voice and web response system to receive open-label dovitinib ( 500 mg orally according to a 5-days-on and 2-days-off schedule ) or sorafenib ( 400 mg orally twice daily ) in a 1:1 ratio .